1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6A0BD6E8E8116C71165257E5B0027DD70
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/medical-affairs-role-in-health-economics-outcomes-research
18
19
2018.97.9.168
21
22
23best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Health Outcomes

Medical Affairs’ Role in Health Economics & Outcomes Research

ID: POP-259


Features:

19 Info Graphics

26 Data Graphics

400+ Metrics

6 Narratives

12 Best Practices


Pages: 58


Published: Pre-2019


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
The Medical Affairs (MA) function plays an increasingly important role in health outcomes (HO) information exchange between biopharmaceutical companies and key external stakeholders such as patients, payers and providers. As a result, MA organizations seek innovative opportunities to grow their health outcomes data generation and utilization skills to maximize business impact and scientific rigor.


Best Practices, LLC undertook a study to identify opportunity fronts and strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.

Note: Segmentation analysis was key to examining trends and effective practices. Benchmark findings were segmented on two criteria: Company Size and HO Group Maturity.


Industries Profiled:
Biotech; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Amgen; Astellas; AstraZeneca; Axon Pharma; Baxter BioScience; Bayer; Boehringer Ingelheim; Eisai; Incyte; Insys Therapeutics; Jazz Pharmaceuticals; Lilly; Lundbeck; Merck; Merz Pharma; MannKind Corporation; Onyx Pharmaceuticals; ProStrakan; Purdue Pharma; Roche; Sanofi; UCB Pharma; Upsher-Smith

Study Snapshot

This study engaged 23 executives from 23 leading life sciences companies. Segmentation analysis was key to examining trends and effective practices. We created segments based on two criteria: Company Size and HO Group Maturity.

Key Findings

· Longevity of HO Groups: HO programs are common, but they represent a young initiative for many of the benchmark class. While 96% of the benchmark class have a HO program, about 44% have had it in place for three years or less.

· Medical Affairs’ Involvement in HO Activities: Medical Affairs is heavily involved in the clinical and scientific research aspects of health outcomes activities. About half of the Medical Affairs groups lead in developing clinical protocols for outcomes research and delivering scientific presentations / speeches.

Table of Contents

· Executive Summary pp. 3-13
· Research Objectives & Methodology pp. 3
· Participating Companies pp. 4
· Segments & Abbreviations pp. 5-6
· Key Findings & Insights pp. 7-13
· Longevity of HO Groups pp. 14-16
· HO Leadership pp. 17-20
· HO Reporting Structure pp. 21-24
· HO Group Staffing pp. 25-31
· MA’s Role in HO Activities pp.32-38
· MA’s Role in Collecting HO Data pp.39-42
· Utilization of HO Data pp. 43-50
· Impact of HO Data on Decisions pp. 51-56

List of Charts & Exhibits

· Longevity of Health Outcomes Group(s) - How long has the HO program been in place at your company?
· Leadership - Who heads the Health Outcomes group(s)?
· Reporting Structure - To whom does the Health Outcomes group(s) report?
· Number of Office-Based and Field-Based HO full-time employees (FTEs)?
· % Field-Based HO FTEs
· Core Field-Based HO Responsibilities
· Medical Affairs’ Involvement in HO Activities
· MA’s Role in Collecting HO Data
· HO Data and Different Stakeholders – Patients, Payers & Providers
· Effect of HO Data on Critical Decisions